<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="case-report">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">3zrvT9CBLqN349nKr7Ssfmf</article-id>
      <article-id pub-id-type="other">00013</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009000100013</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09200113</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009000100013</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato de Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Hematoma subdural de medula espinhal associada ao uso de anticoagulante oral</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Flato</surname>
            <given-names>Uri Adrian Prync</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rheder</surname>
            <given-names>Paulo S&#233;rgio</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Guimar&#227;es</surname>
            <given-names>Helio Penna</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Flato</surname>
            <given-names>Elias Silva</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cretella</surname>
            <given-names>Paulo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <institution content-type="orgname">Hospital Villa Lobos</institution>
        <country country="BR">Brasil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>01</month>
        <year>2009</year>
      </pub-date>
      <volume>92</volume>
      <issue>1</issue>
      <fpage>e1</fpage>
      <lpage>e3</lpage>
      <history>
        <date date-type="accepted">
          <day>27</day>
          <month>08</month>
          <year>2008</year>
        </date>
        <date date-type="rev-recd">
          <day>27</day>
          <month>08</month>
          <year>2008</year>
        </date>
        <date date-type="received">
          <day>18</day>
          <month>07</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>O hematoma subdural de medula espinhal (HSDME) &#233; uma complica&#231;&#227;o rara decorrente do uso de antagonistas de vitamina K (AVK) e de diagnostico dif&#237;cil. Este artigo apresenta um caso com complica&#231;&#227;o amea&#231;adora &#224; vida: um paciente octogen&#225;rio portador de fibrila&#231;&#227;o atrial de in&#237;cio recente em uso de AVK. A hist&#243;ria e o exame f&#237;sico inicialmente se apresentavam normais, associados com a eleva&#231;&#227;o dos valores de coagulograma supraterap&#234;uticos (INR &gt; 10). Ap&#243;s 24 horas da admiss&#227;o hospitalar, o paciente apresentou tetraparesia progressiva, evidenciando na resson&#226;ncia nuclear magn&#233;tica (RNM) de medula espinhal um HSDME (Figura 1). Ap&#243;s revers&#227;o completa da hipocoagula&#231;&#227;o e interven&#231;&#227;o neurocir&#250;rgica o paciente obteve melhora do quadro neurol&#243;gico.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Hematoma subdural espinal</kwd>
        <kwd>medula espinhal</kwd>
        <kwd>coagula&#231;&#227;o sangu&#237;nea</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>04</day>
        <month>02</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>RELATO DE CASO</bold>
    </p>
    <p>
      <bold>Hematoma subdural de medula espinhal associada ao uso de anticoagulante oral</bold>
    </p>
    <p>
      <bold>Uri Adrian Prync Flato; Paulo S&#233;rgio Rheder; Helio Penna Guimar&#227;es; Elias Silva Flato; Paulo Cretella</bold>
    </p>
    <p>Hospital Villa Lobos, S&#227;o Paulo, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p>O hematoma subdural de medula espinhal (HSDME) &#233; uma complica&#231;&#227;o rara decorrente do uso de antagonistas de vitamina K (AVK) e de diagnostico dif&#237;cil. Este artigo apresenta um caso com complica&#231;&#227;o amea&#231;adora &#224; vida: um paciente octogen&#225;rio portador de fibrila&#231;&#227;o atrial de in&#237;cio recente em uso de AVK. A hist&#243;ria e o exame f&#237;sico inicialmente se apresentavam normais, associados com a eleva&#231;&#227;o dos valores de coagulograma supraterap&#234;uticos (INR &gt; 10). Ap&#243;s 24 horas da admiss&#227;o hospitalar, o paciente apresentou tetraparesia progressiva, evidenciando na resson&#226;ncia nuclear magn&#233;tica (RNM) de medula espinhal um HSDME (<xref ref-type="fig" rid="fig1">Figura 1</xref>). Ap&#243;s revers&#227;o completa da hipocoagula&#231;&#227;o e interven&#231;&#227;o neurocir&#250;rgica o paciente obteve melhora do quadro neurol&#243;gico.</p>
    <p><bold>Palavras-chave: </bold> Hematoma subdural espinal, medula espinhal, coagula&#231;&#227;o sangu&#237;nea.</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>Atualmente, estima-se em 2,5 milh&#245;es<sup>1</sup> o n&#250;mero de pessoas portadoras de fibrila&#231;&#227;o atrial nos Estados Unidos. O tratamento dessa ocorr&#234;ncia com antagonistas de vitamina K (AVK) implica a redu&#231;&#227;o relativa de risco (RRR) de eventos cerebrovasculares de 68%<sup>2</sup>. Com o aumento da expectativa de vida, estima-se que 10% da popula&#231;&#227;o mundial acima de 80 anos ser&#225; portadora dessa arritmia card&#237;aca.</p>
    <p>Em rela&#231;&#227;o &#224; utiliza&#231;&#227;o de antagonistas de vitamina K (AVK), os estudos<sup>3</sup> cl&#237;nicos demonstram uma incid&#234;ncia de sangramento maior de 0,3%-0,5% por ano e sangramento sistema nervoso central de 0,2% por ano. Deve-se ressaltar que esses dados s&#227;o derivados de pacientes conduzidos e monitorizados adequadamente quanto a par&#226;metro de anticoagula&#231;&#227;o. N&#227;o fizeram parte desse cen&#225;rio os pacientes que abandonaram o tratamento no per&#237;odo inicial dos estudos (fase de inclus&#227;o ou <italic>run-in</italic>), os exclu&#237;dos por quest&#245;es socioculturais e aqueles que pertenciam a alguns subgrupos de alta preval&#234;ncia de complica&#231;&#245;es cardioemb&#243;licas, como os idosos. Dados da pr&#225;tica cl&#237;nica di&#225;ria, ou seja, provenientes de pacientes do mundo real, s&#227;o provavelmente superiores aos relatados anteriormente, entretanto n&#227;o h&#225; adequada evid&#234;ncia sob o ponto de vista metodol&#243;gico, e apenas estudos retrospectivos com n&#250;mero de pacientes reduzidos s&#227;o considerados para tal. Abdelhafiz e Wheeldon<sup>4</sup>, em um estudo retrospectivo de pacientes em uso de AVK, evidenciaram a incid&#234;ncia de sangramento maior ao redor de 3,4% ao ano. Esses pacientes foram monitorados em ambulat&#243;rios n&#227;o especializados.</p>
    <p>S&#227;o fatores considerados independentes para risco de sangramento associado &#224; utiliza&#231;&#227;o de AVK: intensidade do efeito anticoagulante (INR &gt;3,0), caracter&#237;sticas do paciente (idade superior a 75 anos), utiliza&#231;&#227;o de drogas que interfiram com o AVK e tempo de tratamento. Em raz&#227;o do baixo n&#250;mero de pacientes octogen&#225;rios inclu&#237;dos nos estudos cl&#237;nicos de ACO (anticoagula&#231;&#227;o oral), esse grupo padece de incertezas e sugest&#245;es de ACO com alvos terap&#234;uticos reduzidos (INR 1,8-2,5). Sua utiliza&#231;&#227;o deve ser baseada em aspectos sociocomportamentais e aplica&#231;&#227;o rotineira de modelos de riscos de sangramentos<sup>5</sup>, para orientar a terap&#234;utica correta e diminuir riscos ao paciente. Recentemente, Hart e cols.<sup>6</sup> realizaram um estudo duplo-cego randomizado em pacientes octogen&#225;rios, no qual se compararam AVK e aspirina. Os autores constataram uma redu&#231;&#227;o de 40% em eventos cerebrovasculares isqu&#234;micos associada &#224; taxa semelhante de sangramento entre os dois grupos.</p>
    <fig id="fig1">
      <graphic xlink:href="1678-4170-abc-92-01-00e1-00013-gf01.jpg"/></fig>
    <p>Recentemente, atualizaram-se as diretrizes<sup>7</sup> do manuseio de AVK, especialmente a utiliza&#231;&#227;o dos ant&#237;dotos desse f&#225;rmaco relacionado com a apresenta&#231;&#227;o clinica do paciente e o n&#237;vel de anticoagula&#231;&#227;o (<xref ref-type="fig" rid="fig13q1">Quadro 1</xref>).</p>
    <p content-type="asset">
      <fig id="fig13q1">
        <graphic xlink:href="1678-4170-abc-92-01-00e1-00013-gf02.jpg"/></fig>
    </p>
    <p>As complica&#231;&#245;es relacionadas a esse tratamento podem ser, muitas vezes, devastadoras. Talvez a implementa&#231;&#227;o de medidas educativas e de estrat&#233;gias para aumentar a ader&#234;ncia dos pacientes aos AVK e a cria&#231;&#227;o de cl&#237;nicas especializadas de anticoagula&#231;&#227;o possibilitem o sucesso terap&#234;utico e a diminui&#231;&#227;o de eventos adversos s&#233;rios.</p>
    <p>O hematoma subdural de medula espinhal (HSDME)<sup>8</sup> &#233; uma situa&#231;&#227;o de emerg&#234;ncia, e seu imediato reconhecimento e tratamento s&#227;o imperativos. A despeito dos recursos de imagens dispon&#237;veis atualmente, o atraso no reconhecimento do HSDME e a precis&#227;o do m&#233;todo diagn&#243;stico ideal s&#227;o obst&#225;culos que dever&#227;o ser vencidos. As principais causas desse grave diagn&#243;stico s&#227;o o uso de anticoagulantes orais, a iatrogenia durante pun&#231;&#227;o lombar, trauma espinhal e tumora&#231;&#245;es.</p>
    <p>A apresenta&#231;&#227;o cl&#237;nica &#233; vari&#225;vel, desde sintomas neurol&#243;gicos focais, disfun&#231;&#227;o vesical at&#233; sintomas inespec&#237;ficos como dor lombar, mimetizando lombociatalgia. A extens&#227;o do hematoma, assim como sua disposi&#231;&#227;o em rela&#231;&#227;o &#224; medula espinhal, pode levar &#224; s&#237;ndrome de compress&#227;o medular e a danos irrevers&#237;veis &#224; medula secund&#225;rios &#224; isquemia. Os principais fatores relacionados com les&#227;o medular irrevers&#237;vel s&#227;o: tempo de compress&#227;o medular (in&#237;cio dos sintomas &gt;12 horas) e retardo do tratamento cir&#250;rgico para descompress&#227;o. O "padr&#227;o-ouro" para diagn&#243;stico das altera&#231;&#245;es de estruturas medulares &#233; a resson&#226;ncia nuclear magn&#233;tica (RNM)<sup>9,10</sup>. Comumente n&#227;o se consegue discernir entre hematomas subdurais e epidurais de medula espinhal em sua fase hiperaguda (&lt; 12 horas), entretanto, por meio de reconstru&#231;&#227;o multiplanar, podem-se visualizar cortes sagitais em toda sua extens&#227;o craniocaudal.</p>
    <p>As op&#231;&#245;es terap&#234;uticas descritas na literatura em casos de HSDME s&#227;o: revers&#227;o inicial da causa precipitante como revers&#227;o total da anticoagula&#231;&#227;o, tratamento cir&#250;rgico descompressivo (laminectomia, incis&#227;o na dura-m&#225;ter e retirada do co&#225;gulo), drenagem percut&#226;nea e/ou tratamento conservador.</p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>Este caso demonstra o impacto da hipercoagula&#231;&#227;o em um indiv&#237;duo octogen&#225;rio, associada &#224; rara complica&#231;&#227;o, de dif&#237;cil diagn&#243;stico e que necessita de interven&#231;&#245;es r&#225;pidas. Conclu&#237;mos que a suspei&#231;&#227;o de acometimento medular em pacientes anticoagulados que apresentam sinais neurol&#243;gicos m&#237;nimos deve ser considerada, particularmente quando faixas de seguran&#231;a dos valores de INR (2-3,5) est&#227;o acima do esperado.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="back" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Uri Adrian Prync Flato </p>
        <p> Rua Artur de Almeida,167 - Vila Mariana </p>
        <p> - 04011-080 - S&#227;o Paulo - SP - Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="uriflato@cardiol.br">uriflato@cardiol.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 18/07/08; revisado recebido em 27/08/08; aceito em 27/08/08.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Go AS, Hylek    EM, Phillips KA, Chang Y, Henault LE, Selby JY, et al. Prevalence of diagnosed    atrial fibrillation in adults: national implications for rhythm management and    stroke prevention; the AnTicoagulation and Risk Factors in Atrial Fibrillation    (ATRIA) Study. JAMA. 2001; 285: 2370-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study</article-title>
          <source>JAMA</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>2370</fpage>
          <lpage>5</lpage>
          <volume>285</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Go</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Hylek</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Phillips</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Henault</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Selby</surname>
              <given-names>JY</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Schulman S,    Beyth RJ, Kearon C, Levine MN; American College of Chest Physicians. Hemorrhagic    complications of anticoagulant and thrombolytic treatment*American College of    Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).    Chest. 2008; 133 (6 Suppl.): 257S-298S.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines</article-title>
          <source>Chest</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>257S</fpage>
          <lpage>298S</lpage>
          <issue>6</issue>
          <volume>133</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Schulman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Beyth</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Kearon</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>MN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Risk factors    for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis    of pooled data from five randomized controlled trials. Arch Intern Med. 1994;    154: 1449-57.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials</article-title>
          <source>Arch Intern Med</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>1449</fpage>
          <lpage>57</lpage>
          <volume>154</volume>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Abdelhafiz AH,    Wheeldon NM. Results of an open-label, prospective study of anticoagulant therapy    for atrial fibrillation in an outpatient anticoagulation clinic. Clin Ther.    2004; 26: 1470-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic</article-title>
          <source>Clin Ther</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1470</fpage>
          <lpage>8</lpage>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Abdelhafiz</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Wheeldon</surname>
              <given-names>NM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Beyth RJ, Quinn    LM, Landefeld CS. Prospective evaluation of an index for predicting the risk    of major bleeding in outpatients treated with warfarin. Am J Med. 1998; 105:    91-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin</article-title>
          <source>Am J Med</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>91</fpage>
          <lpage>9</lpage>
          <volume>105</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Beyth</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Quinn</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Landefeld</surname>
              <given-names>CS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Hart RG, Pearce    LA, Aguilar, MI. Adjusted-dose warfarin versus aspirin for preventing stroke    in patients with atrial fibrillation. Ann Intern Med. 2007; 147: 590-2.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation</article-title>
          <source>Ann Intern Med</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>590</fpage>
          <lpage>2</lpage>
          <volume>147</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hart</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Pearce</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Aguilar</surname>
            </name>
            <name>
              <surname>MI</surname>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Ansell J, Hirsh    J, Hylek E, Jacobson A, Crowther M, Palareti G, et al. Pharmacology and management    of the vitamin K antagonists. American College of Chest Physicians Evidence-Based    Clinical Practice Guidelines .(8th Edition). Chest. 2008; 133: 160S-198S.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Pharmacology and management of the vitamin K antagonists. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines .(8th Edition)</article-title>
          <source>Chest</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>160S</fpage>
          <lpage>198S</lpage>
          <volume>133</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ansell</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hirsh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hylek</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Jacobson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Crowther</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Palareti</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Braun P, Nogu&#233;s-Melendez    P, Fornas G, Guijarro G, Latorre O. Hyper acute spinal subdural haematoma: MRI    features in two cases. Eur J Radiol Extra. 2005; 55: 5-10.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Hyper acute spinal subdural haematoma: MRI features in two cases</article-title>
          <source>Eur J Radiol Extra</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>5</fpage>
          <lpage>10</lpage>
          <volume>55</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Braun</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Nogu&#233;s-Melendez</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Fornas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Guijarro</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Latorre</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Post MJ, Becerra    JL, Madsen PW, Puckett W, Quencer RM, Bunge RP. Acute spinal subdural haematoma:    MR and CT findings with pathologic correlates. Am J Neuroradiol. 1994; 15 (10):    1895-905.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Acute spinal subdural haematoma: MR and CT findings with pathologic correlates</article-title>
          <source>Am J Neuroradiol</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>1895</fpage>
          <lpage>905</lpage>
          <issue>10</issue>
          <volume>15</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Post</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Becerra</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Madsen</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Puckett</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Quencer</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Bunge</surname>
              <given-names>RP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Pedraza Guti&#233;rrez    S, Coll Masfarr&#233; S, Casta&#241;o Duque CH, Suesc&#250;n M, Rovira    Ca&#241;nellas A. Hyper acute spinal subdural haematoma as a complication    of lumbar spinal anaesthesia: MRI. Neuroradiology. 1999; 41: 910-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Hyper acute spinal subdural haematoma as a complication of lumbar spinal anaesthesia: MRI</article-title>
          <source>Neuroradiology</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>910</fpage>
          <lpage>4</lpage>
          <volume>41</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pedraza Guti&#233;rrez</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Coll Masfarr&#233;</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Casta&#241;o Duque</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Suesc&#250;n</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rovira Ca&#241;nellas</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato de Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="es">Hematoma subdural de la m&#233;dula espinal asociado al uso de anticoagulante oral</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>El hematoma subdural espinal (HSE) es una complicaci&#243;n rara proveniente del uso de antagonistas de vitamina K (AVK) y de diagnostico dif&#237;cil. Este art&#237;culo presenta un caso con complicaci&#243;n amenazadora para la vida: un paciente octogenario portador de fibrilaci&#243;n auricular de inicio reciente, en uso de AVK. Inicialmente, la historia y el examen f&#237;sico se presentaban normales, asociados a la elevaci&#243;n de los valores de coagulograma supra terap&#233;uticos (INR &gt; 10). Tras 24 horas del ingreso hospitalario, el paciente present&#243; tetraparesia progresiva. Al realizarse una resonancia nuclear magn&#233;tica (RNM) de m&#233;dula espinal, se evidenci&#243; un HSE (Figura 1). Tras reversi&#243;n completa de la hipocoagulaci&#243;n e intervenci&#243;n neuroquir&#250;rgica el paciente obtuvo mejora del cuadro neurol&#243;gico.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Hematoma subdural espinal</kwd>
        <kwd>m&#233;dula espinal</kwd>
        <kwd>coagulaci&#243;n sangu&#237;nea</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>RELATO DE CASO</bold>
      </p>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Hematoma subdural de la m&#233;dula espinal asociado al uso de anticoagulante oral </bold>
          </label>
          <p>
            <bold>Uri Adrian Prync Flato; Paulo S&#233;rgio Rheder; Helio Penna Guimar&#227;es; Elias Silva Flato; Paulo Cretella</bold>
          </p>
        </fn>
      </p>
      <p>Hospital Villa Lobos, S&#227;o Paulo, SP - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p>El hematoma subdural espinal (HSE) es una complicaci&#243;n rara proveniente del uso de antagonistas de vitamina K (AVK) y de diagnostico dif&#237;cil. Este art&#237;culo presenta un caso con complicaci&#243;n amenazadora para la vida: un paciente octogenario portador de fibrilaci&#243;n auricular de inicio reciente, en uso de AVK. Inicialmente, la historia y el examen f&#237;sico se presentaban normales, asociados a la elevaci&#243;n de los valores de coagulograma supra terap&#233;uticos (INR &gt; 10). Tras 24 horas del ingreso hospitalario, el paciente present&#243; tetraparesia progresiva. Al realizarse una resonancia nuclear magn&#233;tica (RNM) de m&#233;dula espinal, se evidenci&#243; un HSE (<xref ref-type="fig" rid="fig1-body2">Figura 1</xref>). Tras reversi&#243;n completa de la hipocoagulaci&#243;n e intervenci&#243;n neuroquir&#250;rgica el paciente obtuvo mejora del cuadro neurol&#243;gico.</p>
      <p><bold>Palabras clave:</bold> Hematoma subdural espinal, m&#233;dula espinal, coagulaci&#243;n sangu&#237;nea.</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>En los d&#237;as actuales, se estima en 2,5 milh&#245;es<sup>1</sup> el n&#250;mero de personas portadoras de fibrilaci&#243;n atrial en Estados Unidos. El tratamiento de esa ocurrencia con antagonistas de vitamina K (AVK) implica la reducci&#243;n relativa de riesgo (RRR) de eventos cerebrovasculares del 68%<sup>2</sup>. Con el aumento de la expectativa de vida, se estima que el 10% de la poblaci&#243;n mundial con m&#225;s de 80 a&#241;os ser&#225; portadora de esa arritmia cardiaca.</p>
      <p>En relaci&#243;n con la utilizaci&#243;n de antagonistas de vitamina K, los estudios<sup>3</sup> cl&#237;nicos evidencian una incidencia de sangrado superior al 0,3%-0,5% al a&#241;o y sangrado del sistema nervioso central del 0,2% al a&#241;o. Se debe resaltar que esos datos resultan de pacientes orientados y monitorizados adecuadamente en cuanto al par&#225;metro de anticoagulaci&#243;n. No formaron parte de ese grupo los pacientes que abandonaron el tratamiento en el per&#237;odo inicial de los estudios (fase de inclusi&#243;n o <bold><italic>run-in</italic></bold>), los excluidos por cuestiones socioculturales y los que pertenec&#237;an a algunos subgrupos de alta prevalencia de complicaciones cardioemb&#243;licas, como los adultos ancianos. Datos de la pr&#225;ctica cl&#237;nica diaria, es decir, provenientes de pacientes del mundo real, son probablemente superiores a los relatados anteriormente. Sin embargo, no hay evidencia adecuada bajo el punto de vista metodol&#243;gico, y s&#243;lo estudios retrospectivos con n&#250;mero de pacientes reducidos se pueden tomar en consideraci&#243;n. Abdelhafiz y Wheeldon<sup>4</sup>, en un estudio retrospectivo de pacientes en uso de AVK, evidenciaron la incidencia de sangrado mayor alrededor del 3,4% al a&#241;o. Se monitore&#243; a los pacientes en ambulatorios no especializados.</p>
      <p>Siguen a continuaci&#243;n los factores considerados independientes para el riesgo de sangrado asociado a la utilizaci&#243;n de AVK: la intensidad del efecto anticoagulante (INR &gt;3,0); las caracter&#237;sticas del paciente (edad superior a 75 a&#241;os); la utilizaci&#243;n de f&#225;rmacos que interfieran en el AVK y el tiempo de tratamiento. En raz&#243;n del bajo n&#250;mero de pacientes octogenarios incluidos en los estudios cl&#237;nicos de anticoagulaci&#243;n oral (ACO), ese grupo padece de incertidumbres y sugerencias de ACO con blancos terap&#233;uticos reducidos (INR 1,8-2,5). Se debe basar su utilizaci&#243;n en aspectos sociocomportamentales y en la aplicaci&#243;n rutinaria de modelos de riesgos de sangrados<sup>5</sup>, para orientar la terap&#233;utica correcta y disminuir los riesgos al paciente. Recientemente, Hart et al<sup>6</sup> realizaron un estudio doble ciego randomizado en pacientes octogenarios, en lo que se compararon AVK y aspirina. Los autores constataron una reducci&#243;n del 40% en eventos cerebrovasculares isqu&#233;micos asociada a la tasa semejante de sangrado entre los dos grupos.</p>
      <p>Hace poco, se actualizaron las directrices<sup>7</sup> del manejo de AVK, espec&#237;ficamente la utilizaci&#243;n de los ant&#237;dotos de ese f&#225;rmaco relacionado a la presentaci&#243;n cl&#237;nica del paciente y el nivel de anticoagulaci&#243;n (<xref ref-type="fig" rid="es_13c1-body2">Cuadro 1</xref>).</p>
      <p content-type="asset">
        <fig id="es_13c1-body2">
          <graphic xlink:href="1678-4170-abc-92-01-00e1-00013-gf01-es.jpg"/></fig>
      </p>
      <p>Las complicaciones relacionadas a ese tratamiento pueden ser, muchas veces, devastadoras. Tal vez la implementaci&#243;n de medidas educativas y de estrategias para incrementar la adhesi&#243;n de los pacientes a los AVK y la creaci&#243;n de cl&#237;nicas especializadas de anticoagulaci&#243;n posibiliten el &#233;xito terap&#233;utico y la reducci&#243;n de eventos adversos severos.</p>
      <p>El hematoma subdural espinal<sup>8</sup> es una situaci&#243;n de emergencia, y su inmediato reconocimiento y tratamiento son imperativos. Sobre los recursos de im&#225;genes disponibles actualmente, el retraso en el reconocimiento del HSE y la precisi&#243;n del m&#233;todo diagn&#243;stico ideal son obst&#225;culos que deber&#225;n ser ultrapasados. Las principales causas de ese grave diagn&#243;stico son el uso de anticoagulantes orales, la iatrogenia durante punci&#243;n lumbar, el trauma espinal y tumoraciones.</p>
      <p>La presentaci&#243;n cl&#237;nica es variable, desde s&#237;ntomas neurol&#243;gicos focales, disfunci&#243;n vesical hasta s&#237;ntomas inespec&#237;ficos como dolor lumbar, lo que mimetiza la lumbociatalgia. La extensi&#243;n del hematoma, tal como su disposici&#243;n en relaci&#243;n con la m&#233;dula espinal, puede resultar en s&#237;ndrome de compresi&#243;n medular y en da&#241;os irreversibles a la m&#233;dula, secundarios a la isquemia. Los principales factores relacionados a la lesi&#243;n medular irreversible son: tiempo de compresi&#243;n medular (inicio de los s&#237;ntomas &gt;12 horas) y retardo del tratamiento quir&#250;rgico para descompresi&#243;n. El est&#225;ndar oro para el diagn&#243;stico de las alteraciones de estructuras medulares es la resonancia nuclear magn&#233;tica (RNM)<sup>9,10</sup>. Normalmente no se logra discernir entre hematomas subdurales y epidurales de m&#233;dula espinal en su fase hiperaguda (&lt; 12 horas), sin embargo, por medio de reconstrucci&#243;n multiplanar, se pueden visualizar cortes sagitales en toda su extensi&#243;n cr&#225;neo-caudal.</p>
      <fig id="fig1-body2">
        <graphic xlink:href="1678-4170-abc-92-01-00e1-00013-gf02-es.jpg"/></fig>
      <p>Las opciones terap&#233;uticas descritas en la literatura en casos de HSE son reversi&#243;n inicial de la causa precipitante como reversi&#243;n total de la anticoagulaci&#243;n, tratamiento quir&#250;rgico descompresivo (laminectom&#237;a, incisi&#243;n en la duramadre y retirada del co&#225;gulo), drenaje percut&#225;neo y/o tratamiento conservador.</p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>Este caso evidencia el impacto de la hipercoagulaci&#243;n en un individuo octogenario, asociada a la rara complicaci&#243;n, de dif&#237;cil diagn&#243;stico y que necesita de intervenciones r&#225;pidas. Concluimos que se debe tomar en cuenta la sospecha de acometimiento medular en pacientes anticoagulados que presentan se&#241;ales neurol&#243;gicos m&#237;nimos, sobre todo cuando intervalos de seguridad de los valores de INR (2-3,5) est&#225;n m&#225;s elevados que lo esperado.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Spine subdural hematoma: a rare complication associated with vitamin K antagonist (VKA)</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>Spinal subdural hematoma (SSDH) is a rare condition, which is difficult to diagnose, related to Vitamin K Antagonist. This a case report of a life-threatening situation in a octogenarian patient with a history of recent atrial fibrillation that received K-Vitamin Antagonist (KVA) therapy. The history and the clinical assessment were normal at the admission, associated with increase in the coagulation parameters (INR &gt;10). Twenty-four hours after the admission, the patient developed progressive tetraparesis and a Magnetic Resonance Imaging (MRI) was performed, disclosing the evidence of a SSDH (Figure 1). An emergency neurosurgical intervention was performed associated with normalization of the coagulation parameters. After the procedure, the patient presented improvement of the neurological symptoms.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Hematoma, subdural spinal</kwd>
        <kwd>spinal cord</kwd>
        <kwd>blood coagulation</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>CASE REPORT</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Spine subdural hematoma: a rare complication associated with vitamin K antagonist (VKA)</bold>
          </label>
          <p>
            <bold>Uri Adrian Prync Flato; Paulo S&#233;rgio Rheder; Helio Penna Guimar&#227;es; Elias Silva Flato; Paulo Cretella</bold>
          </p>
        </fn>
      </p>
      <p>Hospital Villa Lobos, S&#227;o Paulo, SP - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p>Spinal subdural hematoma (SSDH) is a rare condition, which is difficult to diagnose, related to Vitamin K Antagonist. This a case report of a life-threatening situation in a octogenarian patient with a history of recent atrial fibrillation that received K-Vitamin Antagonist (KVA) therapy. The history and the clinical assessment were normal at the admission, associated with increase in the coagulation parameters (INR &gt;10). Twenty-four hours after the admission, the patient developed progressive tetraparesis and a Magnetic Resonance Imaging (MRI) was performed, disclosing the evidence of a SSDH (<xref ref-type="fig" rid="fig1-body3">Figure 1</xref>). An emergency neurosurgical intervention was performed associated with normalization of the coagulation parameters. After the procedure, the patient presented improvement of the neurological symptoms.</p>
      <p><bold>Key words:</bold> Hematoma, subdural spinal; spinal cord; blood coagulation.</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>It is estimated that 2.5 million people<sup>1</sup> currently have atrial fibrillation in the USA, in whom treatment with vitamin K antagonists (VKA) implies in the relative decrease (RD) in cardiovascular events of 68%<sup>2</sup>. With the increase in life expectancy, it is estimated that 10% of the world's population older than 80 years will present this heart arrhythmia.</p>
      <p>Regarding the use of vitamin K antagonists (VKA), the clinical studies<sup>3</sup> have demonstrated an incidence of major bleeding of 0.3%-0.5% a year and central nervous system bleeding of 0.2% a year. It is worth mentioning that these data were obtained from patients that were adequately managed and monitored regarding the anticoagulation parameter; in this scenario, some patients were excluded from the study: patients that abandoned the treatment during the initial study period (inclusion or Run-in phase), those excluded due to sociocultural questions, and a small number of patients in some subgroups with a high prevalence of cardioembolic complications, such as the elderly. Data from daily clinical practice, i.e., from "real-life patients", are probably higher than those previously reported; however, adequate evidence under a methodological point of view is not available and only retrospective studies with a small number of patients are considered for such. Abdelhafiz and Wheeldon<sup>4</sup>, in a retrospective study of patients using VKA, showed an incidence of major bleeding of around 3.4% a year, monitored in non-specialized outpatient clinics. The following are considered independent risk factors for bleeding associated to the use of VKA: intensity of the anticoagulant effect (INR &gt;3.0), characteristics of the patient (age older than 75 yrs), use of drugs that interfere with the VKA and time of treatment. Due to the small number of octogenarian patients included in clinical studies of oral anticoagulants (OAC), this group endures reservations and suggestions of OAC with reduced therapeutic targets (INR 1.8-2.5). Its use must be based on socio-behavioral aspects and routine use of bleeding risk models<sup>5</sup>, to conduct the adequate therapy and decrease the risks to the patient. Recently, Hart et al<sup>6</sup> carried out a randomized, double-blind study in octogenarian patients, comparing VKA aspirin and observed a decrease of 40% in ischemic cerebrovascular events associated to a similar rate of bleeding between the two groups.</p>
      <p>The VKA management directives<sup>7</sup> have been recently updated, especially regarding the use of this drug antidotes related to the patient's clinical presentation and the level of anticoagulation (<xref ref-type="fig" rid="en_13c1-body3">Chart 1</xref>).</p>
      <p content-type="asset">
        <fig id="en_13c1-body3">
          <graphic xlink:href="1678-4170-abc-92-01-00e1-00013-gf01-en.jpg"/></fig>
      </p>
      <p>The complications related to this treatment can very often be devastating and perhaps, the implementation of educational measures, strategies to improve patients' adherence to VKA associated to the implementation of clinics that are specialized in anticoagulation can allow the therapeutic success as well as the decrease in severe adverse events.</p>
      <p>The spinal subdural hematoma (SSDH)<sup>8</sup> is an emergency situation and its prompt recognition and treatment are mandatory. In spite of the currently available imaging techniques, the delay in the recognition of the SSDH and the precision of the ideal diagnostic method are obstacles to be overcome. The main causes of this severe diagnosis are the use of oral anticoagulants, iatrogenic event during lumbar puncture, spinal trauma and tumors.</p>
      <p>The clinical presentation varies from localized symptoms, vesical dysfunction, to unspecific symptoms such as lumbar pain, mimicking lumbosciatic syndrome. The extension of the hematoma, as well as its location in relation to the spinal cord, can lead to medullary compression syndrome and irreversible damage to the spinal cord, secondary to ischemia. The main factors related to irreversible spinal cord injury are: time of medullary compression (start of the symptoms &gt; 12 hours) and the delay in the surgical treatment for decompression. The gold standard for the diagnosis of medullary structure alterations is the magnetic resonance imaging (MRI)<sup>9,10</sup>; usually, it is impossible to differentiate between spinal subdural and epidural hematomas in their hyperacute phases (&lt; 12 hours); however, through the multiplane reconstruction one can visualize, through sagittal slices, its entire head-caudal extension.</p>
      <fig id="fig1-body3">
        <graphic xlink:href="1678-4170-abc-92-01-00e1-00013-gf02-en.jpg"/></fig>
      <p>The therapeutic options described in the literature in cases of SSDH are: initial reversion of the precipitating cause, such as total reversion of the anticoagulation, decompressive surgical treatment (laminectomy, incision in the dura-mater and thrombus removal), percutaneous drainage and/or conservative treatment.</p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>This case demonstrates the impact of hypercoagulation on an octogenarian individual, associated to a rare complication, difficult to diagnose and that requires rapid interventions. We conclude that the suspicion of medullary involvement in anticoagulated patients that present minimal neurological symptoms must be considered, particularly when safety ranges of INR values (2-3,5) are above the expected ones.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
